An experimental gene therapy known as AMT-130 has become the first treatment to successfully slow the progression of Huntington’s disease, marking a potential breakthrough in the fight against neurodegenerative disorders.…
As reported by HD Buzz, a significant step forward for Huntington’s disease (HD) research, Roche has announced that the first patient has been dosed in its new gene therapy clinical…
University of Copenhagen researchers have been studying the cause of Huntington’s disease in order to potentially develop a treatment. They have determined that failure of glial cell maturation is a…
According to an article originally published by HDBuzz, a number of exciting advances have been made in the development of treatments that hope to treat thousands of potential Huntington's disease…
According to an article published on BioPortfolio, earlier this week, biotechnology company Vybion Incorporated secured orphan drug designation for its highly experimental Huntington's disease drug INT41. About Huntington's Disease Huntington's…
Approximately one in 15,000 people have a defect in their HTT gene and the outcome of that defect is ultimately life-ending. It's called Huntington's disease, or HD, and the average…
We’ve written before about the frankly awful Huntington’s disease. The devastating way it strips a person of their motor functions, cognition, and day-to-day quality of life. Treatments remain relatively scarce…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
